Loading…
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Summary A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scen...
Saved in:
| Published in: | Wiener Klinische Wochenschrift 2022, Vol.134 (1-2), p.63-72 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c446t-e0ada073c317fb2f98de7e7ebdadd9da4f2d145db1657fabc9beed7bf39f3b453 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c446t-e0ada073c317fb2f98de7e7ebdadd9da4f2d145db1657fabc9beed7bf39f3b453 |
| container_end_page | 72 |
| container_issue | 1-2 |
| container_start_page | 63 |
| container_title | Wiener Klinische Wochenschrift |
| container_volume | 134 |
| creator | Bartsch, Rupert Gampenrieder, Simon Peter Rinnerthaler, Gabriel Petru, Edgar Egle, Daniel Petzer, Andreas Balic, Marija Pluschnig, Ursula Sliwa, Thamer Singer, Christian |
| description | Summary
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus. |
| doi_str_mv | 10.1007/s00508-021-01987-9 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8813714</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2623890308</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-e0ada073c317fb2f98de7e7ebdadd9da4f2d145db1657fabc9beed7bf39f3b453</originalsourceid><addsrcrecordid>eNp9kU1LxDAQhoMouq7-AQ_SoyDVSdM2zUVYFnWFBUH0HCYfXSv9WJNU8N8b3VX0InOYwzzvO8O8hJxQuKAA_NIDFFClkNEUqKh4KnbIhJaUpbzkdJdMAHKWFiwrDsih9y8ArMg53ScHLOoEE-WE3DytDQZrktnog2uwT4KzGDrbhwTb1eCa8NwlTZ8srh-y86SzAX3A0OhERc6HRGOvrTsiezW23h5v-5Q83Vw_zhfp8v72bj5bpjrPy5BaQIPAmWaU1yqrRWUsj6UMGiMM5nVmaF4YRcuC16i0UNYarmomaqbygk3J1cZ3ParOGh3PdNjKtWs6dO9ywEb-nfTNs1wNb7KqKOM0jwZnWwM3vI7WB9k1Xtu2xd4Oo5dZmbFKAIMqotkG1W7w3tn6Zw0F-RmA3AQgYwDyKwApouj094E_ku-PR4BtAB9H_co6-TKMro9P-8_2A8zQk8s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2623890308</pqid></control><display><type>article</type><title>Updated Austrian treatment algorithm in HER2+ metastatic breast cancer</title><source>Springer Nature</source><creator>Bartsch, Rupert ; Gampenrieder, Simon Peter ; Rinnerthaler, Gabriel ; Petru, Edgar ; Egle, Daniel ; Petzer, Andreas ; Balic, Marija ; Pluschnig, Ursula ; Sliwa, Thamer ; Singer, Christian</creator><creatorcontrib>Bartsch, Rupert ; Gampenrieder, Simon Peter ; Rinnerthaler, Gabriel ; Petru, Edgar ; Egle, Daniel ; Petzer, Andreas ; Balic, Marija ; Pluschnig, Ursula ; Sliwa, Thamer ; Singer, Christian</creatorcontrib><description>Summary
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.</description><identifier>ISSN: 0043-5325</identifier><identifier>EISSN: 1613-7671</identifier><identifier>DOI: 10.1007/s00508-021-01987-9</identifier><identifier>PMID: 35089396</identifier><language>eng</language><publisher>Vienna: Springer Vienna</publisher><subject>Algorithms ; Antibodies, Monoclonal, Humanized - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols ; Austria ; Breast Neoplasms - drug therapy ; Consensus Report ; Endocrinology ; Female ; Gastroenterology ; Humans ; Internal Medicine ; Medicine ; Medicine & Public Health ; Pneumology/Respiratory System ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - therapeutic use ; Trastuzumab - therapeutic use</subject><ispartof>Wiener Klinische Wochenschrift, 2022, Vol.134 (1-2), p.63-72</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-e0ada073c317fb2f98de7e7ebdadd9da4f2d145db1657fabc9beed7bf39f3b453</citedby><cites>FETCH-LOGICAL-c446t-e0ada073c317fb2f98de7e7ebdadd9da4f2d145db1657fabc9beed7bf39f3b453</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35089396$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bartsch, Rupert</creatorcontrib><creatorcontrib>Gampenrieder, Simon Peter</creatorcontrib><creatorcontrib>Rinnerthaler, Gabriel</creatorcontrib><creatorcontrib>Petru, Edgar</creatorcontrib><creatorcontrib>Egle, Daniel</creatorcontrib><creatorcontrib>Petzer, Andreas</creatorcontrib><creatorcontrib>Balic, Marija</creatorcontrib><creatorcontrib>Pluschnig, Ursula</creatorcontrib><creatorcontrib>Sliwa, Thamer</creatorcontrib><creatorcontrib>Singer, Christian</creatorcontrib><title>Updated Austrian treatment algorithm in HER2+ metastatic breast cancer</title><title>Wiener Klinische Wochenschrift</title><addtitle>Wien Klin Wochenschr</addtitle><addtitle>Wien Klin Wochenschr</addtitle><description>Summary
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.</description><subject>Algorithms</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols</subject><subject>Austria</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Consensus Report</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Gastroenterology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Pneumology/Respiratory System</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - therapeutic use</subject><subject>Trastuzumab - therapeutic use</subject><issn>0043-5325</issn><issn>1613-7671</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kU1LxDAQhoMouq7-AQ_SoyDVSdM2zUVYFnWFBUH0HCYfXSv9WJNU8N8b3VX0InOYwzzvO8O8hJxQuKAA_NIDFFClkNEUqKh4KnbIhJaUpbzkdJdMAHKWFiwrDsih9y8ArMg53ScHLOoEE-WE3DytDQZrktnog2uwT4KzGDrbhwTb1eCa8NwlTZ8srh-y86SzAX3A0OhERc6HRGOvrTsiezW23h5v-5Q83Vw_zhfp8v72bj5bpjrPy5BaQIPAmWaU1yqrRWUsj6UMGiMM5nVmaF4YRcuC16i0UNYarmomaqbygk3J1cZ3ParOGh3PdNjKtWs6dO9ywEb-nfTNs1wNb7KqKOM0jwZnWwM3vI7WB9k1Xtu2xd4Oo5dZmbFKAIMqotkG1W7w3tn6Zw0F-RmA3AQgYwDyKwApouj094E_ku-PR4BtAB9H_co6-TKMro9P-8_2A8zQk8s</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Bartsch, Rupert</creator><creator>Gampenrieder, Simon Peter</creator><creator>Rinnerthaler, Gabriel</creator><creator>Petru, Edgar</creator><creator>Egle, Daniel</creator><creator>Petzer, Andreas</creator><creator>Balic, Marija</creator><creator>Pluschnig, Ursula</creator><creator>Sliwa, Thamer</creator><creator>Singer, Christian</creator><general>Springer Vienna</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>2022</creationdate><title>Updated Austrian treatment algorithm in HER2+ metastatic breast cancer</title><author>Bartsch, Rupert ; Gampenrieder, Simon Peter ; Rinnerthaler, Gabriel ; Petru, Edgar ; Egle, Daniel ; Petzer, Andreas ; Balic, Marija ; Pluschnig, Ursula ; Sliwa, Thamer ; Singer, Christian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-e0ada073c317fb2f98de7e7ebdadd9da4f2d145db1657fabc9beed7bf39f3b453</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Algorithms</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols</topic><topic>Austria</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Consensus Report</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Gastroenterology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Pneumology/Respiratory System</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - therapeutic use</topic><topic>Trastuzumab - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bartsch, Rupert</creatorcontrib><creatorcontrib>Gampenrieder, Simon Peter</creatorcontrib><creatorcontrib>Rinnerthaler, Gabriel</creatorcontrib><creatorcontrib>Petru, Edgar</creatorcontrib><creatorcontrib>Egle, Daniel</creatorcontrib><creatorcontrib>Petzer, Andreas</creatorcontrib><creatorcontrib>Balic, Marija</creatorcontrib><creatorcontrib>Pluschnig, Ursula</creatorcontrib><creatorcontrib>Sliwa, Thamer</creatorcontrib><creatorcontrib>Singer, Christian</creatorcontrib><collection>SpringerOpen</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Wiener Klinische Wochenschrift</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bartsch, Rupert</au><au>Gampenrieder, Simon Peter</au><au>Rinnerthaler, Gabriel</au><au>Petru, Edgar</au><au>Egle, Daniel</au><au>Petzer, Andreas</au><au>Balic, Marija</au><au>Pluschnig, Ursula</au><au>Sliwa, Thamer</au><au>Singer, Christian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Updated Austrian treatment algorithm in HER2+ metastatic breast cancer</atitle><jtitle>Wiener Klinische Wochenschrift</jtitle><stitle>Wien Klin Wochenschr</stitle><addtitle>Wien Klin Wochenschr</addtitle><date>2022</date><risdate>2022</risdate><volume>134</volume><issue>1-2</issue><spage>63</spage><epage>72</epage><pages>63-72</pages><issn>0043-5325</issn><eissn>1613-7671</eissn><abstract>Summary
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.</abstract><cop>Vienna</cop><pub>Springer Vienna</pub><pmid>35089396</pmid><doi>10.1007/s00508-021-01987-9</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0043-5325 |
| ispartof | Wiener Klinische Wochenschrift, 2022, Vol.134 (1-2), p.63-72 |
| issn | 0043-5325 1613-7671 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8813714 |
| source | Springer Nature |
| subjects | Algorithms Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols Austria Breast Neoplasms - drug therapy Consensus Report Endocrinology Female Gastroenterology Humans Internal Medicine Medicine Medicine & Public Health Pneumology/Respiratory System Receptor, ErbB-2 - genetics Receptor, ErbB-2 - therapeutic use Trastuzumab - therapeutic use |
| title | Updated Austrian treatment algorithm in HER2+ metastatic breast cancer |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A16%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Updated%20Austrian%20treatment%20algorithm%20in%20HER2+%20metastatic%20breast%20cancer&rft.jtitle=Wiener%20Klinische%20Wochenschrift&rft.au=Bartsch,%20Rupert&rft.date=2022&rft.volume=134&rft.issue=1-2&rft.spage=63&rft.epage=72&rft.pages=63-72&rft.issn=0043-5325&rft.eissn=1613-7671&rft_id=info:doi/10.1007/s00508-021-01987-9&rft_dat=%3Cproquest_pubme%3E2623890308%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c446t-e0ada073c317fb2f98de7e7ebdadd9da4f2d145db1657fabc9beed7bf39f3b453%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2623890308&rft_id=info:pmid/35089396&rfr_iscdi=true |